Dermatol. praxi. 2020;14(1):39-42 | DOI: 10.36290/der.2020.003

Guselkumab (Tremfya)

MUDr. Jan Hugo, doc. MUDr. Spyridon Gkalpakiotis, Ph.D., MBA
Dermatovenerologická klinika 3. LF UK a FNKV, Praha

As knowledge of the pathogenesis of psoriasis deepened, the crucial importance of interleukin 23 (IL-23) was recognized. This was also reflected by the development of new therapies. Guselkumab is the first approved biologic drug with specific inhibition of IL-23. Our article summarizes the therapeutic potential of this drug and recapitulates the latest information on the effect of interleukin 23.

Keywords: psoriasis, biologic therapy, interleukin 23, guselkumab.

Published: March 25, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hugo J, Gkalpakiotis S. Guselkumab (Tremfya). Dermatol. praxi. 2020;14(1):39-42. doi: 10.36290/der.2020.003.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Vanaclocha F, et al. Immune‑mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study. Actas Dermosifiliogr. 2015 Jan‑Feb; 106(1): 35-43. Go to original source... Go to PubMed...
    2. Koo S, et al. Infectious complications associated with immunomodulating biologic agents. Infect Dis ClinNorth Am 2010; 24: 285. Go to original source... Go to PubMed...
    3. Tonel G, et al. Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol. 2010 Nov 15; 185(10): 5688-5691. Go to original source... Go to PubMed...
    4. Aggarwal S, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003; 78: 1910-1914. Go to original source... Go to PubMed...
    5. Lønnberg AS, et al. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014; 7: 251-259. Go to original source... Go to PubMed...
    6. Gaffen SL, et al. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014 Sep; 14(9): 585-600. Go to original source... Go to PubMed...
    7. Cheuk S, et al. Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis; J Immunol 2014; 192: 3111-3120. Go to original source... Go to PubMed...
    8. Megna M, et al. Guselkumab for the treatment of psoriasis; Exp Opin Biol Ther 2018; 18(4): 459-468. Go to original source...
    9. Langley RG, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‑blind, phase III NAVIGATE trial. Br J Dermatol. 2018 Jan; 178(1): 114-123. Go to original source...
    10. Reich K, et al. Guselkumab versus secukinumab for the treatment of moderate‑to‑severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019 Sep 7; 394(10201): 831-839. Go to original source...
    11. Souhrn údajů o přípravku Tremfya 100mg, datum revize textu: 26. 11. 2018.
    12. Griffiths CEM, et al. Maintenance of response with up to 4 years of continuous guselkumab treatment: Results from the VOYAGE 1 phase 3 trial. Presented at: 2019 Fall Clinical Dermatology Conference; October 17-20, 2019; Las Vegas, NV.
    13. Foley P, et al. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 Jun 1; 154(6): 676-683. Go to original source...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.